Literature DB >> 14769898

Human immunodeficiency virus type 1 subtype C Gag virus-like particle boost substantially improves the immune response to a subtype C gag DNA vaccine in mice.

Ann Jaffray1, Enid Shephard2, Joanne van Harmelen3, Carolyn Williamson4,3, Anna-Lise Williamson5,4,3, Edward P Rybicki4,1.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) subtype C is the predominant HIV in southern Africa, and is the target of a number of recent vaccine candidates. It has been proposed that a heterologous prime/boost vaccination strategy may result in stronger, broader and more prolonged immune responses. Since HIV-1 Gag Pr55 polyprotein can assemble into virus-like particles (VLPs) which have been shown to induce a strong cellular immune response in animals, we showed that a typical southern African subtype C Pr55 protein expressed in insect cells via recombinant baculovirus could form VLPs. We then used the baculovirus-produced VLPs as a boost to a subtype C HIV-1 gag DNA prime vaccination in mice. This study shows that a low dose of HIV-1 subtype C Gag VLPs can significantly boost the immune response to a single subtype C gag DNA inoculation in mice. These results suggest a possible vaccination regimen for humans.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14769898     DOI: 10.1099/vir.0.19396-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

1.  From plant virology to vaccinology: The road less travelled.

Authors:  Edward Rybicki
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen.

Authors:  Natasha Larke; Aileen Murphy; Christoph Wirblich; Denise Teoh; Marie J Estcourt; Andrew J McMichael; Polly Roy; Tomás Hanke
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

3.  Use of the piggyBac transposon to create HIV-1 gag transgenic insect cell lines for continuous VLP production.

Authors:  Alisson G Lynch; Fiona Tanzer; Malcolm J Fraser; Enid G Shephard; Anna-Lise Williamson; Edward P Rybicki
Journal:  BMC Biotechnol       Date:  2010-03-31       Impact factor: 2.563

4.  HIV-1 sub-type C chimaeric VLPs boost cellular immune responses in mice.

Authors:  Sirika Pillay; Enid G Shephard; Ann E Meyers; Anna-Lise Williamson; Edward P Rybicki
Journal:  J Immune Based Ther Vaccines       Date:  2010-11-19

5.  Robust immunity to an auxotrophic Mycobacterium bovis BCG-VLP prime-boost HIV vaccine candidate in a nonhuman primate model.

Authors:  Gerald K Chege; Wendy A Burgers; Helen Stutz; Ann E Meyers; Rosamund Chapman; Agano Kiravu; Rubina Bunjun; Enid G Shephard; William R Jacobs; Edward P Rybicki; Anna-Lise Williamson
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

6.  Abrogation of contaminating RNA activity in HIV-1 Gag VLPs.

Authors:  Ziyaad Valley-Omar; Ann E Meyers; Enid G Shephard; Anna-Lise Williamson; Edward P Rybicki
Journal:  Virol J       Date:  2011-10-06       Impact factor: 4.099

Review 7.  Plant-made vaccines for humans and animals.

Authors:  Edward P Rybicki
Journal:  Plant Biotechnol J       Date:  2010-03-11       Impact factor: 9.803

8.  Stability studies of HIV-1 Pr55gag virus-like particles made in insect cells after storage in various formulation media.

Authors:  Alisson Lynch; Ann E Meyers; Anna-Lise Williamson; Edward P Rybicki
Journal:  Virol J       Date:  2012-09-18       Impact factor: 4.099

9.  Biological and biochemical characterization of HIV-1 Gag/dgp41 virus-like particles expressed in Nicotiana benthamiana.

Authors:  Sarah A Kessans; Mark D Linhart; Nobuyuki Matoba; Tsafrir Mor
Journal:  Plant Biotechnol J       Date:  2013-03-19       Impact factor: 9.803

10.  Expression of HIV-1 antigens in plants as potential subunit vaccines.

Authors:  Ann Meyers; Ereck Chakauya; Enid Shephard; Fiona L Tanzer; James Maclean; Alisson Lynch; Anna-Lise Williamson; Edward P Rybicki
Journal:  BMC Biotechnol       Date:  2008-06-23       Impact factor: 2.563

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.